Adamas Pharmaceuticals ADMS shares are trading lower on Thursday after the company reconfirmed it will not initiate further Phase 3 development in MSW.
Adamas Pharmaceuticalsdiscovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Adamas Pharmaceuticals shares were trading down 3.8% at $2.75 at time of publication on Thursday. The stock has a 52-week high of $7.78 and a 52-week low of $1.90.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
